Tactile Systems (TCMD) Stock Forecast & Price Target

Tactile Systems Tech is well positioned because it serves a large, under-penetrated, and under-diagnosed lymphedema market while pairing that opportunity with a growing Airway Clearance franchise that has become the #1 share player in its segment. The company’s FY25 transformation, including a revamped sales force, better back-office processes, and productivity tools, is now translating into stronger territory productivity, 1Q26 revenue of $75.3M, and gross margins of 76.5%, with FY26 guidance raised to $360M-$368M. Its outlook is further strengthened by structural tailwinds from the Medicare NCD, stable reimbursement, improving diagnosis through LymphaTech, and a favorable valuation of about 1.4x NTM EV/Sales versus peers at 3.5x.

Tactile Systems Tech is viewed negatively because its growth depends on improved uptake in commercial channels and a more efficient sales organization, yet management still faces risks from non-selling tasks, Medicare documentation burdens, and confusion over coverage. Competition in airway clearance and varying doctor opinions on pneumatic compression as a standalone treatment add pressure, while the sales force only slipped to 332 reps in 2Q26 from 335 in 1Q26, limiting near-term operating leverage. Although adjusted EBITDA is guided at $49M to $51M and revenue is modeled to reach $408.5M, the company still needs easier comps, better processes, and macro help to defend margins and sustain execution.